• Raymond James has maintained its "Outperform" rating for Johnson & Johnson (NYSE:JNJ) and raised its price target from $174 to $209.
• Johnson & Johnson increased its 2025 sales forecast following a strong quarterly earnings report, surpassing Wall Street's expectations.
• The company's strategic decision to spin off its orthopedics business into a standalone entity is expected to contribute to its growth prospects.

On October 15, 2025, Raymond James maintained its "Outperform" rating for Johnson & Johnson (NYSE:JNJ). At the time, JNJ was priced at $190.85. Raymond James also raised its price target for JNJ from $174 to $209, indicating confidence in the company's future performance.

Johnson & Johnson recently increased its 2025 sales forecast after a strong quarterly earnings report that exceeded Wall Street's expectations. This positive outlook likely influenced Raymond James' decision to maintain its "Outperform" rating and raise the price target. The company's strategic move to spin off its orthopedics business into a standalone entity may also contribute to its growth prospects.

Currently, JNJ is trading at $190.85, with a slight decrease of 0.05, reflecting a percentage change of approximately -0.03%. The stock has fluctuated between a low of $185.97 and a high of $194.39 today. Over the past year, JNJ has reached a high of $194.40 and a low of $140.68, showcasing its resilience in the market.

Johnson & Johnson's market capitalization stands at approximately $459.63 billion, indicating its significant presence in the healthcare industry. With a trading volume of 11.27 million shares, the stock remains actively traded, reflecting investor interest and confidence in the company's future performance.